Improving the response rate in patients with cancer relies on three different approaches: (1) elucidating the mechanisms underlying the lack of response to PD-1 antibody treatment, (2) developing novel predictive markers, and (3) developing an effective combination therapy. This evidence concerns the gene PDCD1 and cancer.